The levels of nitric oxide in megaloblastic anemia
Yükleniyor...
Dosyalar
Tarih
2009
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Journal of Hematology
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Öz: Amaç: Bu çalışmada siyanokobalamin ile tedavi edilen megaloblastik anemi ile nitrik asit degranülasyon ürünleri olan nitrat ve nitrit arasındaki ilişki araştırıldı. Yöntem ve Gereçler: Çalışmaya 16’sı erkek, 14’ü kadın olan toplam 30 megaloblastik anemili hasta alındı. Hastalara retikü losit krizi görülene kadar 1.000 ?g/gün dozunda siyanokobalamin intramüsküler olarak uygulandı. Kontrol grubu tamamen sağlıklı 15’i erkek, 15’i kadın toplam 30 kişiden oluşturuldu. Nitrik oksit düzeyleri tedavi öncesinde ölçüldü ve retikülosit sayısının en yüksek seviyesinde tekrar ölçülerek karşılaştırıldı. Bulgular: Tedavi öncesindeki ortalama plazma direk nitrit seviyesi ?mol/dl olarak 24,86±3,87, total nitrit 60,56±7,01 ve nitrat 36,02±5,24 bulundu. Buna karşılık kontrol grubunda sırasıyla 15,48±3,05, 38,92±4,42 ve 22,77±6,04 bulundu. Tedavi sonrası plazma direk nitrit, total nitrit ve nitrat seviyesinin tedavi öncesine göre istatistiksel olarak anlamlı derecede azaldığı tespit edildi (p<0.001). Sonuç: Nitrik oksit düzeyleri megaloblastik anemide artmaktadır. Bu çalışma megaloblastik anemide nitrik oksit düzeylerin- deki anormalliklerin B12 replasman tedavisi ile düzeldiğini ortaya koymaktadır.
Abstract: Objective: The purpose of this study was to investigate the relationship between nitric oxide degradation products (nitrate and nitrite) levels and megaloblastic anemia which is treated with cyalocobalamin. Materials and Methods: A total of 30 patients with megaloblastic anemia (16 Male, 14 Female) were included in the study. Cyanocobalamin was administered (1.000 &#956;g/day intramuscularly) until the reticulocyte crisis occurred to the normal range. The control group consisted of 30 healthy subjects (15 Male, 15 Female). Nitric oxide levels were measured before treatment and compared with the values obtained during peak reticulocyte count. Results: Plasma direct nitrite, total nitrite and nitrate levels were 24,86±3,87, 60.56±7,01 and 36,02±5,24 in before treatment versus 15,48±3,05, 38,92±6,44 and 22,77±6,04 &#956;mol/dl in after treatment, respectively. Plasma direct nitrite, total nitrite and nitrate levels were significantly lower in after treatment compared with the before treatment (p<0.001). Conclusion: Nitric oxide levels are seen to increase in megaloblastic anemia. This study suggested that abnormalities in the nitric oxide levels in megaloblastic anemia are restored by vitamin B12 replacement therapy.
Abstract: Objective: The purpose of this study was to investigate the relationship between nitric oxide degradation products (nitrate and nitrite) levels and megaloblastic anemia which is treated with cyalocobalamin. Materials and Methods: A total of 30 patients with megaloblastic anemia (16 Male, 14 Female) were included in the study. Cyanocobalamin was administered (1.000 &#956;g/day intramuscularly) until the reticulocyte crisis occurred to the normal range. The control group consisted of 30 healthy subjects (15 Male, 15 Female). Nitric oxide levels were measured before treatment and compared with the values obtained during peak reticulocyte count. Results: Plasma direct nitrite, total nitrite and nitrate levels were 24,86±3,87, 60.56±7,01 and 36,02±5,24 in before treatment versus 15,48±3,05, 38,92±6,44 and 22,77±6,04 &#956;mol/dl in after treatment, respectively. Plasma direct nitrite, total nitrite and nitrate levels were significantly lower in after treatment compared with the before treatment (p<0.001). Conclusion: Nitric oxide levels are seen to increase in megaloblastic anemia. This study suggested that abnormalities in the nitric oxide levels in megaloblastic anemia are restored by vitamin B12 replacement therapy.
Açıklama
Anahtar Kelimeler
Kaynak
Turkish Journal of Hematology
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
26
Sayı
4
Künye
ERKURT M. A,AYDOĞDU İ,BAYRAKTAR N,KUKU İ,KAYA E (2009). The levels of nitric oxide in megaloblastic anemia. Turkish Journal of Hematology, 26(4), 197 - 200.
